Moderna shares surge after increased US investment in vaccine research

361
SHARE

On Monday, Moderna CEO Stephane Bancel commented, “It’s a really optimistic scenario. It could be November. Again, at this stage, it’s impossible for us to know precisely. It will depend on the event rate, the attack rate of infection.”

Trial results could be available as early as October of this year.

As the pandemic continues to surge across the United States, a heightened sense of urgency for a workable vaccine can be felt in all corners of the country. According to the World Health Organization, over 150 vaccines are under development with 25 in human trials. This includes human trials for experimental vaccines from pharmaceutical giants Pfizer and AstraZeneca.

Only time will tell if a viable vaccine can be developed, tested, and receive FDA approval by the start of 2021 — the clock is ticking.

————————————————–

Have a story you want USA Herald to cover? Submit a tip here and if we think it’s newsworthy, we’ll follow up on it.

Want guaranteed coverage? We also offer contract journalism here.  Just be sure you’re comfortable giving up editorial control, because our journalists are dogged and will follow the story through to it’s conclusion. The story will be published to our exacting standards, without regard for your preferred slant.